Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) has been assigned an average rating of “Buy” from the six ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $33.40.
Several research analysts have recently issued reports on RPHM shares. LADENBURG THALM/SH SH began coverage on shares of Reneo Pharmaceuticals in a research note on Monday, November 22nd. They issued a “buy” rating and a $45.00 target price on the stock. Zacks Investment Research cut shares of Reneo Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, HC Wainwright assumed coverage on shares of Reneo Pharmaceuticals in a report on Tuesday, December 21st. They set a “buy” rating and a $28.00 target price for the company.
Several hedge funds and other institutional investors have recently made changes to their positions in RPHM. Deutsche Bank AG purchased a new stake in shares of Reneo Pharmaceuticals in the second quarter worth $35,000. JPMorgan Chase & Co. purchased a new stake in shares of Reneo Pharmaceuticals in the second quarter worth $73,000. California State Teachers Retirement System bought a new position in shares of Reneo Pharmaceuticals during the second quarter worth $81,000. New York State Common Retirement Fund bought a new position in shares of Reneo Pharmaceuticals during the second quarter worth $121,000. Finally, Tudor Investment Corp Et Al bought a new position in shares of Reneo Pharmaceuticals during the second quarter worth $125,000. 75.22% of the stock is owned by hedge funds and other institutional investors.
Reneo Pharmaceuticals (NASDAQ:RPHM) last announced its earnings results on Thursday, November 11th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). As a group, equities analysts predict that Reneo Pharmaceuticals will post -3.44 EPS for the current year.
About Reneo Pharmaceuticals
Reneo Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V.
Featured Story: Elliott Wave Theory
Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.